Magle Chemoswed announces confirmation of manufacturing order for delivery in 2022.

01/09/2021

Magle Chemoswed announces confirmation of a large order of Isradipine for a new customer for delivery in the second quarter of 2022.

Magle Chemoswed has received an order of Isradipine for delivery in the second quarter of 2022, the order value is SEK10m. Magle Chemoswed holds the regulatory approval for the manufacture and supply of Isradipine. Isradipine is an active pharmaceutical ingredient that is formulated to act as a calcium channel blocker of the dihydropyridine class. It is usually prescribed for the treatment of high blood pressure to reduce the risk of stroke and heart attack.
 
“Magle Chemoswed’s dedication to niche products and high-quality manufacturing capabilities continues to be attractive to the market as we see from the recently concluded deal on Isradipine. Our business development team continue to work tirelessly to increase our market reach and develop new relationships using our established product profile,” said Justin Pierce, Magle Chemoswed’s CEO.

Contacts

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglegroup.com

About Us

Magle Chemoswed is a unique international contract development manufacturing company dedicated to bringing ideas to product for customers alongside building our own product pipeline based on our patented technology base. As an integrated company, we have extensive capabilities across the value chain, from the discovery, development and manufacture of medicines and medical devices that rely on our patented and trade secret protected technology platform.

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

Magle Chemoswed announces confirmation of manufacturing order for delivery in 2022.